Additional Relevant Details
As previously reported, adult patients treated with ARX-04 in this study experienced a mean pain intensity difference of 2.9 from a baseline of 8.1 on a validated 0 – 10 numeric rating scale at 60 minutes, meeting the study's primary objective. Injuries sustained by patients in SAP302 included fractures, sprains/strains, lacerations and burns, among others.  Study participants tolerated ARX-04 well, with nausea (9%), somnolence (5%) and vomiting (4%) comprising the most commonly reported adverse events.The study additionally concluded that ARX-04 had no overall impact on cognitive function.